Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration
- PMID: 19755476
- DOI: 10.1093/ndt/gfp437
Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration
Abstract
Background: The accumulation of larger and protein-bound toxins is involved in the uraemic syndrome but their elimination by dialysis therapy remains difficult. In the present study, the impact of the albumin permeability of recently introduced advanced high-flux dialysis membranes on the removal of such substances was tested in haemodialysis and online post-dilution haemodiafiltration.
Methods: Two types of polyethersulfone membranes only differing in albumin permeability (referred as PU- and PU+) were compared in eight patients on maintenance dialysis in a prospective cross-over manner. Treatment settings were identical for individual patients: time 229 +/- 22 min; blood flow rate 378 +/- 33 mL/min; dialysate flow rate 500 mL/min; substitution flow rate in haemodiafiltration 94 +/- 9 mL/min. Removal of the protein-bound compounds p-cresyl sulfate (pCS) and indoxyl sulfate (IS) was determined by reduction ratios (RRs), dialytic clearances and mass in continuously collected dialysate. In addition, the elimination of the low-molecular weight (LMW) proteins beta(2)-microglobulin, cystatin c, myoglobin (myo), free retinol-binding protein (rbp) and albumin was measured.
Results: Plasma levels of the protein-bound toxins were significantly decreased by all treatment forms. However, the decreases were comparable between dialysis membranes and between haemodialysis and haemodiafiltration. The RRs of total pCS ranged between 40.4 +/- 25.3 and 47.8 +/- 10.3% and of total IS between 50.4 +/- 2.6 and 54.6 +/- 8.7%. Elimination of free protein-bound toxins as assessed by their mass in dialysate closely correlated positively with the pre-treatment plasma concentrations being r = 0.920 (P < 0.001) for total pCS and r = 0.906 (P < 0.001) for total IS, respectively. Compared to haemodialysis, much higher removal of all LMW proteins was found in haemodiafiltration. Dialysis membrane differences were only obvious in haemodialysis for the larger LMW proteins myo and rbp yielding significantly higher RRs for PU+ (myo 46 +/- 9 versus 37 +/- 9%; rbp 18 +/- 5 versus 15 +/- 5%; P < 0.05). Additionally, the albumin loss varied between membranes and treatment modes being undetectable with PU- in haemodialysis and highest with PU+ in haemodiafiltration (1430 +/- 566 mg).
Conclusions: The elimination of protein-bound compounds into dialysate is predicted by the level of pre-treatment plasma concentrations and depends particularly on diffusion. Lacking enhanced removal in online post-dilution haemodiafiltration emphasizes the minor significance of convection for the clearance of these solutes. Compared to LMW proteins, the highly protein-bound toxins pCS and IS are less effectively eliminated with all treatment forms. For a sustained decrease of pCS and IS plasma levels, alternative strategies promise to be more efficient therapy forms.
Similar articles
-
Removal of protein-bound uraemic toxins by haemodialysis.Blood Purif. 2013;35 Suppl 2:20-5. doi: 10.1159/000350843. Epub 2013 May 3. Blood Purif. 2013. PMID: 23676831 Review.
-
Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.Nephrol Dial Transplant. 2011 Aug;26(8):2624-30. doi: 10.1093/ndt/gfq803. Epub 2011 Feb 10. Nephrol Dial Transplant. 2011. PMID: 21310741 Clinical Trial.
-
Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.Nephrol Dial Transplant. 2007 Jul;22(7):2006-12. doi: 10.1093/ndt/gfm065. Epub 2007 Apr 27. Nephrol Dial Transplant. 2007. PMID: 17468506
-
Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration.Scand J Clin Lab Invest. 2008;68(8):685-91. doi: 10.1080/00365510802047693. Scand J Clin Lab Invest. 2008. PMID: 18609120 Clinical Trial.
-
The removal of protein-bound solutes by dialysis.J Ren Nutr. 2012 Jan;22(1):203-6. doi: 10.1053/j.jrn.2011.10.011. J Ren Nutr. 2012. PMID: 22200443 Review.
Cited by
-
Cystatin C in children on chronic hemodialysis.Pediatr Nephrol. 2013 Apr;28(4):647-53. doi: 10.1007/s00467-012-2366-7. Epub 2012 Nov 21. Pediatr Nephrol. 2013. PMID: 23179198
-
Protective effect of activated charcoal against progression of chronic kidney disease: A randomized clinical study.J Med Life. 2023 Sep;16(9):1310-1315. doi: 10.25122/jml-2023-0128. J Med Life. 2023. PMID: 38107705 Free PMC article. Clinical Trial.
-
Overexposure to Bisphenol A and Its Chlorinated Derivatives of Patients with End-Stage Renal Disease during Online Hemodiafiltration.Biomolecules. 2019 Aug 22;9(9):403. doi: 10.3390/biom9090403. Biomolecules. 2019. PMID: 31443526 Free PMC article.
-
Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-Cresol Sulfate in Hemodialysis Patients: Results From an In Vitro Study and An In Vivo Pilot Trial (xuanro4-Nature 3.2).Toxins (Basel). 2020 Mar 10;12(3):170. doi: 10.3390/toxins12030170. Toxins (Basel). 2020. PMID: 32164382 Free PMC article. Clinical Trial.
-
Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.Toxins (Basel). 2021 Jun 29;13(7):450. doi: 10.3390/toxins13070450. Toxins (Basel). 2021. PMID: 34209560 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials